Ingen appoints director of r&d

Aims to increase sales of in vitro diagnostic (IVD) kits

Ingen Biosciences, a French developer of advanced in vitro diagnostic kits for clinical use, has appointed Karine Mignon-Godefroy as director of research & development.

Mignon-Godefroy joins the firm to generate sales of its first proprietary in vitro diagnostic (IVD) kit. These IVD kits are based on the firm’s specialist knowledge in proteomics and expertise in synthesising new recombinant antigens. Mignon-Godefroy will be responsible for identifying clinically relevant recombinant antigens as potential markers for the detection of infectious diseases found in prosthetic replacements, and to develop innovative IVD kits for clinical use.

‘Dr Mignon-Godefroy’s 15 years’ experience in biotechnology, depth of knowledge and skills will be a major contribution to our on-going r&d efforts,’ said Jean-Pierre Hermet, chief executive of Ingen Biosciences. ‘Her arrival will also strengthen the team, which has made significant inroads into developing products based on innovative technologies.'

Mignon-Godefroy joins Ingen Biosciences from the blood virus division of Bio-Rad, a manufacturer and distributor of products for a range of technologies including proteomics, where she was director of international projects.

You may also like

Manufacturing

Bracco enters cell therapy manufacturing with microbubble-based cell selection technology

Bracco Imaging is expanding into cell therapy manufacturing with a bead-free cell selection and activation technology based on its clinically validated microbubble platform
Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Regulatory

ECHA adds two hazardous chemicals to list of substances of very high concern

Companies are responsible for managing the risks of these chemicals and giving customers and consumers information on their safe use
Manufacturing

New manufacturing line from Adragos granted regulatory approval from Swissmedic

The approval of the new, state-of-the-art facility follows a comprehensive modernisation programme in 2024/2025 that has focussed on ensuring the future-readiness of the plant
Regulatory

NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages

NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant MHRA-approved licences and creating dedicated NHS purchasing arrangements to improve long-term supply resilience
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Subscribe now